BFIM
KPTI icon

Beese Fulmer Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Beese Fulmer Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-43
Closed -$12K – 382
2020
Q2 		$12K Buy
+43
New +$12.7K ﹤0.01% 459

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Beese Fulmer Investment Management's KPTI Position: Q3 2020 in Review

Beese Fulmer Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 43 shares — an estimated $12K sold.

Beese Fulmer Investment Management first reported a position in KPTI in Q2 2020 and held it in 1 quarter. The position peaked at $12K in Q2 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

  • Beese Fulmer Investment Management reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Beese Fulmer Investment Management sold 43 Karyopharm Therapeutics shares in Q3 2020, an estimated $12K.
  • Beese Fulmer Investment Management first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 1 quarter.
  • Beese Fulmer Investment Management's Karyopharm Therapeutics position peaked at $12K in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on Beese Fulmer Investment Management's 13F filing for Q3 2020, filed 8 Oct 2020.